| Chronic Obstructive Airway Disease
Stiolto Respimat vs Breo Ellipta
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Stiolto Respimat vs Breo Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreo Ellipta has a higher rate of injection site reactions vs Stiolto Respimat based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breo Ellipta but not Stiolto Respimat, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stiolto Respimat
Breo Ellipta
At A Glance
Oral inhalation
Once daily
LAMA/LABA
Oral inhalation
Once daily
ICS/LABA combination
Indications
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Contraindications
- Use of LABA without inhaled corticosteroid in patients with asthma
- Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
Adverse Reactions
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Pharmacology
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stiolto Respimat
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Stiolto Respimat
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Stiolto Respimat
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Stiolto Respimat.
No savings programs available for Breo Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Stiolto RespimatView full Stiolto Respimat profile
Breo ElliptaView full Breo Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.